Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP) Reduction (OMT/IOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03590249
Recruitment Status : Enrolling by invitation
First Posted : July 18, 2018
Last Update Posted : September 29, 2021
Sponsor:
Information provided by (Responsible Party):
Hollis King, University of California, San Diego

Brief Summary:
Glaucoma is a group of eye diseases, which in most cases produce increased pressure within the eye (intraocular pressure or IOP). Over time, the elevated IOP causes damage to the optic nerve, which can then lead to visual loss and if unchecked, to complete blindness over the course of years. OMT has been shown to affect cranial structure physiology including the possibility of lowering IOP by improving the drainage of intraocular fluid. This randomized study is designed to obtain data to evaluate the effect of OMT on IOP lowering and, if supportive, provide preliminary data for larger clinical trials.

Condition or disease Intervention/treatment Phase
Glaucoma Procedure: Osteopathic Manipulative Treatment Not Applicable

Detailed Description:

The design of this preliminary pilot trial to be conducted is a double-masked (blind), randomized, No Treatment-controlled, parallel group design to determine the IOP-lowering efficacy and safety of a single osteopathic manipulative treatment (OMT) on intraocular pressure (IOP) in un-medicated confirmed ocular hypertensive (OHT), glaucoma suspect, or subjects who have been diagnosed with glaucoma but who have gone through a medically supervised medication washout period or 4 weeks.

Potential subjects responding to recruitment who are currently on IOP lowering medication will be prescreened and if interested in proceeding will undergo a 4 week medication washout period. Potential subjects not on IOP lowering medication will proceed directly to the Baseline screening visit.

All subjects will be seen for a Baseline Screening Visit followed by a second Baseline Enrollment Visit, during which subjects must satisfy all inclusion criteria and their IOP must qualify in at least one (1) eye, the same eye, at all time points. Qualified subjects will be scheduled for a Study Day 3 Visit. Subjects whose IOP still qualifies at the Visit 3 time point will be randomized in a 1:1 ratio to receive OMT or No Treatment followed by IOP measurements and +7.5 HR (4 PM [± 1 hour]) post-OMT or No Treatment. Follow-up visits will be conducted at Visit 4 (1 day following OMT vs No Treatment), and Visit 5 (1 week following OMT vs No Treatment). Both Visit 4 and Visit 5 will have IOP measured twice.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The design of this preliminary pilot trial is a double-masked (blind), randomized, No Treatment-controlled, parallel group design.
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: The practitioner providing the OMT or No Treatment will not be involved in collecting data for each subject. The practitioner(s) and technicians collecting the data will not be involved in any aspect of the procedure performed (OMT or No Treatment) on the subjects.
Primary Purpose: Treatment
Official Title: Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP) Reduction
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Arm Intervention/treatment
Experimental: Osteopathic Manipulative Treatment (OMT)
Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
Procedure: Osteopathic Manipulative Treatment
Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.

No Intervention: No Intervention
Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.



Primary Outcome Measures :
  1. Intraocular Pressure Change [ Time Frame: 1-day and 1-week post-intervention or no intervention ]
    All vision data are collected by Hamilton Glaucoma Center trained research staff and physicians. The primary outcome measure, IOP (Goldman tonometry) will be collected and read by two people in the "masked IOP" procedure and the readings will be averaged.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Subject inclusion criteria:

  1. Subjects will be of either sex, age 18 years or older, and of any race or eye color.
  2. Subjects with confirmed ocular hypertension (OHT), glaucoma suspects or diagnosed with primary open-angle glaucoma whose IOP was ≥ 20 mmHg at two measurements separated by at least 3 months. If subject already on IOP lowering medication and goes through the 4 week washout, they must still have initial IOP ≥ 20 mmHg at the Baseline I screening visit.
  3. Subjects who do not have visual field defect(s), as determined by Visual Field Analysis within the last year such as "blind spots" and other visual image distortions from normal vision.
  4. Subjects who do not have abnormal cupping of the optic nerve head.
  5. Subjects who do not have narrow angles as determined by gonioscopy (must be at least angle grade 2 to 3; Shaffer Classification Scale) recorded in the subject's patient record or as determined by biomicroscopy.
  6. Subjects who have not been treated with ocular hypotensive agents (or, if they have been treated, not for at least the preceding 4 weeks before Baseline I Screening).
  7. Subjects must satisfy all informed consent requirements.
  8. Subjects whose mean IOP measurements in at least one (1) eye, the same eye(s), must be:

    • Greater than or equal to 20 mmHg at the 8:00 AM time-point on the Screening and Enrollment Visits (1 and 2) and
    • Greater than or equal to 19 mmHg at the 5 PM time-points on the Screening and Enrollment Visits (1 and 2).

Subject exclusion criteria:

  1. Subjects who have had any traumatic brain injury or head trauma, which resulted in upper-spinal fusion which requires metal or plastic screws or plates and/or cranial bone surgery, which involves penetration of the cranial bones and/or implantation of a metal plate.
  2. Subjects who have a concurrent diagnosis of cancer or metastatic disease affecting the head and neck.
  3. Subjects who are less than 18 years old.
  4. Subjects who are lactating, pregnant, or plan to become pregnant in the time planned for the study, to be confirmed by a urine pregnancy if the woman is still menstruating.
  5. Subjects who have a history of chronic or recurrent severe inflammatory eye disease (e.g., scleritis - inflammation of the white part of the eye or uveitis - eye redness, pain and blurred vision) in either eye as determined by patient history and/or examination.
  6. Subjects who have a history of clinically significant or progressive retinal disease in either eye such as retinal degeneration (which is the breakdown of the light-sensitive cells in retina), diabetic retinopathy (involves changes to retinal blood vessels that can cause them to bleed or leak fluid), or retinal detachment which is separation of the retina from the layer of cells behind it with permanent field loss as determined by patient history and/or examination.
  7. Subjects who have a history of serious ocular trauma in either eye within the past six (6) months as determined by patient history and/or examination.
  8. Subjects who have had intraocular surgery in either eye within the past six (6) months as determined by patient history and/or examination.
  9. Subjects who have had ocular laser surgery, which is the use of a laser beam to make a very small hole in the eye tissue (also known as Lasik) in either eye within the past three (3) months as determined by patient history and/or examination.
  10. Subjects who have a history of ocular infection or ocular inflammation in either eye within the past three (3) months as determined by patient history and/or examination.
  11. Subjects who have any abnormality preventing reliable applanation tonometry of either eye (e.g., keratoconus (a thinning of the cornea), cornea (eyes outer most layer) or conjunctiva (the mucous membrane that covers the front of the eye and lines the inside of the eyelids) scarring.
  12. Subjects who have less than a thirty (30) days stable dosing regimen before the Screening and Enrollment Visits (Visits 1 and 2) of any non-ocular medications that may affect IOP, administered by any route and used on a chronic basis. These may include, but are not limited to, alpha agonists, beta-blockers, calcium channel blockers, antimuscarinic agents, and phenothiazines.
  13. Subjects who have other treatments and/or surgeries unrelated to the eye condition scheduled in the time planned for the study.
  14. Subjects who are allergic to Latex, PABA, Proparacaine, or Fluorescein.
  15. Subjects who have had prior surgical or laser treatment for the purpose of lowering their IOP.
  16. Subjects who currently have systemic infections resulting in fever or immunosuppression.
  17. Subjects who have had previous manual medicine or manual therapy with manually guided gentle forces to realign musculoskeletal imbalances or relax strained muscles such as osteopathic manipulative treatment (OMT), chiropractic manipulation, massage within the last 2 months.
  18. Subjects who are unable to give appropriate informed consent due to mental or other limitations.
  19. Additionally, the Principal Investigator may declare any subject ineligible for a valid medical reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03590249


Locations
Layout table for location information
United States, California
Shiley Eye Center, University of California, San Diego
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Investigators
Layout table for investigator information
Principal Investigator: Hollis H King, DO, PhD University of California, San Diego
Layout table for additonal information
Responsible Party: Hollis King, Clinical Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT03590249    
Other Study ID Numbers: 160684
First Posted: July 18, 2018    Key Record Dates
Last Update Posted: September 29, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hollis King, University of California, San Diego:
osteopathic manipulative treatment
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma
Ocular Hypertension
Eye Diseases